• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » EU clears J&J’s $21B Synthes buyout | Wall Street Beat

EU clears J&J’s $21B Synthes buyout | Wall Street Beat

April 19, 2012 By MassDevice staff

MassDevice.com Wall Street Beat

Johnson & Johnson‘s (NYSE:JNJ) move to ditch its DePuy trauma business mollified EuroZone anti-trust regulators enough to win their approval for its $21.3 billion buyout of Synthes Inc.

The deal, announced April 3, would see Biomet Inc. acquire DePuy Orthopaedics’ global trauma assets for $280 million in cash. That eliminated the European Commission’s concerns about "very high combined market shares" in the trauma market, according to a statement emailed to BusinessWeek.

"We obtained remedies to ensure that competition will remain strong in these markets, for the ultimate benefit of patients and social security systems," EU Competition Commissioner Joaquin Almunia said in the statement.

It’s been a year since J&J’s CHF 159-per-share offer for the Swiss orthopedics giant. EU regulators expanded their probe into the deal last November, prompting J&J to seek ways to appease the commission. Last month rumors that the competition panel was set to give its blessing set Wall Street abuzz, but J&J waited until early April to make its deal with Biomet official.

Johnson & Johnson must still satisfy anti-trust officials in the U.S.

The company this week reported adding 12.5% to its bottom line during the first quarter, despite a $271 million after-tax charge on costs associated with its recalled DePuy ASR hip implant.

J&J posted profits of $3.91 billion, or $1.41 per share, on sales of $16.14 billion for the quarter, for essentially flat sales compared with profits of $3.48 billion, or $1.25 EPS, on sales of $16.17 billion during Q1 2011.

 Intuitive Surgical CEO Guthart practices the Buffett rule

One of them, at least.
Gary Guthart, president & CEO of Intuitive Surgical (NSDQ:ISRG), quoted Warren Buffett when asked about a share buyback.

Buffett’s rule is that buybacks only make sense when a company has enough cash to run the business and if its shares are significantly undervalued.

"I think [Buffett] says it right. I think we are happy to emulate his behavior here," Guthart told investors during a conference call discussing ISRG’s Q1 results.
Read more

 Biolase exits Henry Schein deal
Biolase (NSDQ:BLTI) said it’s out of a deal with Henry Schein (NSDQ:HSIC) to buy Waterlase MD Turbo laser systems "at a very advantageous price," noting that the agreement releases all liens on Biolase’s intellectual property portfolio and frees it of obligations to Schein. 
Read more

 SeraCare shareholders OK $81M Linden Capital buyout

SeraCare (NSDQ:SRLS) shareholders approved a $4-per-share buyout offer from Linden Capital Partners worth about $80.8 million.
Read more

 Visium boosts stake in Syneron
Hedge fund Visium Asset Management raised its stake in Syneron Medical Ltd. (NSDQ:ELOS) by more than 28%, saying in a regulatory filing that it owns a 5.3% share of the cosmetic device maker as of March 31. 
Read more

 Derma Sciences closes MedEfficiency buyout
Derma Sciences (NSDQ:DSCI) said it closed its $14.5 million acquisition of MedEfficiency Inc.
Read more

 Funding Roundup

  • Symbios seeks $1.4 million in debt/equity round
  • SynGen lands $5M Series A round

 Analysts’ ups and downs

  • Abbott (NYSE:ABT): Leerink Swann raises price target to $66-$68 from $63-$66, maintains "outperform" rating.
  • Boston Scientific (NYSE:BSX): Barclays Capital maintains "3-underweight" rating, $6 price target.
  • Intuitive Surgical (NSDQ:ISRG): Goldman Sachs raises price target to $604 from $576, maintains "neutral" rating; Cantor Fitzgerald increases price target from $460 to $475, maintains "hold" rating; Dougherty & Co. maintains "buy" rating, raises price target from $650 to $670.
  • St. Jude Medical (NYSE:STJ): Leerink Swann maintains "outperform" rating, lowers price target to $46 from $49.
  • Stryker (NYSE:SYK): Wunderlich Securities maintains "buy" rating, $66 price target.

Filed Under: Mergers & Acquisitions, News Well, Orthopedics, Wall Street Beat Tagged With: Biolase, depuysynthes, Henry Schein Inc., Intuitive Surgical, Johnson and Johnson, Linden Capital Partners, SeraCare Life Sciences Inc., Symbios Medical Products, Syneron Medical Ltd., Visium

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy